Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa
Journal of Bone Oncology · 2023-12 · 43 · 100511
DOI: 10.1016/j.jbo.2023.100511 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Bone Oncology, 2023-12. Verfasst von Ahmad Assi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hematology-Oncology Department, Hotel Dieu de France, Beirut, Lebanon. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Osteosarcoma (OS) is an aggressive primary bone malignancy that metastasizes rapidly. The standard of care has changed little over the previous four decades, and survival rates have plateaued. In this context, tyrosine kinase inhibitors (TKIs) emerge as potential treatments. A literature search was conducted to collect data related to receptor tyrosine kinase genetic alterations and expression in OS specimens. Gene amplification and protein expression of these receptors were linked to prognosis and tumor behavior. Relevant TKIs were evaluated as monotherapies and as parts of combination therapies. Certain TKIs, such as apatinib, regorafenib, and cabozantinib, present a potential therapeutic avenue for OS patients, especially when combined with chemotherapy. Producing long-lasting responses and enhancing quality of life remain key goals in OS treatment. To this effect, optimizing the use of TKIs by identifying biomarkers predictive of response and assessing promising TKIs in larger-scale trials to validate the efficacy and safety outcomes relative to these drugs reported in phase II clinical trials. To this effect, it is necessary to identify biomarkers predictive of response to TKIs in larger-scale trials and to validate the efficacy and safety of these drugs reported in phase II clinical trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hematology-Oncology Department, Hotel Dieu de France, Beirut, Lebanon.
- Orthopedics Department, Hotel Dieu de France, Beirut, Lebanon.
- Orthopedics Department, Brown University, Providence, RI, USA.
Zitieren
APA
Assi, A., Farhat, M., Hachem, M. C. R., Zalaquett, Z., Aoun, M., Daher, M., Sebaaly, A., & Kourie, H. R. (2023). Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa. Journal of Bone Oncology, 43, 100511. https://doi.org/10.1016/j.jbo.2023.100511
Vancouver
Assi A, Farhat M, Hachem MCR, Zalaquett Z, Aoun M, Daher M, et al. Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa. Journal of Bone Oncology. 2023;43:100511. doi:10.1016/j.jbo.2023.100511
BibTeX
@article{Assi2023,
author = {Assi, Ahmad and Farhat, Mohamad and Hachem, Maria Catherine Rita and Zalaquett, Ziad and Aoun, Marven and Daher, Mohammad and Sebaaly, Amer and Kourie, Hampig-Raphaël},
title = {Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa},
journal = {Journal of Bone Oncology},
year = {2023},
volume = {43},
pages = {100511},
doi = {10.1016/j.jbo.2023.100511}
}
EUVIMED